Overview
Thyroid cancer (TC) accounts for 3% of global cancer incidence 1. Treatment decisions are increasingly optimized by risk assessment, molecular profiling, and imaging, with targeted agents modifying the disease's natural history 1.Diagnosis
Diagnosis and treatment require careful assessment at all stages, from initial presentation to long-term follow-up 1.
Recent changes have optimized treatment decisions based on risk assessment, molecular profiling, and imaging assessment 1.Management
Treatment decisions are optimized by risk assessment, molecular profiling, and imaging assessment 1.
Targeted agents have modified the natural history of this disease 1.
The guideline aims to offer a comprehensive and practical overview on the current status and last updates of TC management 1.Key Recommendations
Treatment decisions are optimized by risk assessment, molecular profiling, and imaging assessment 1. (Evidence: Expert opinion)
Targeted agents have modified the natural history of this disease 1. (Evidence: Expert opinion)
The guideline aims to offer a comprehensive and practical overview on the current status and last updates of TC management 1. (Evidence: Expert opinion)References
1 Alonso-Gordoa T, Jimenez-Fonseca P, Martinez-Trufero J, Navarro M, Porras I, Rubió-Casadevall J et al.. SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023). Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2024. link